Table 1. Clinical features of patients at baseline and during the course of the treatment.

					Baseline					HBsAg (log IU/ml)						Anti-HBs Ab status
Case #	Group	Age (year)	Sex	Analog	HBV DNA (IU/ml)	AST (IU/ml)	ALT (IU/ml)	Metavir activity	Metavir fibrosis	W0	W12	W24	W48	W96	W144	W0	W48	W96	W144
1b	NA	55	M	tenofovir	<20	22	21	2	4	2,85	2,97	2,93	2,89	2,83	ND	neg	neg	neg	neg
2		54	M	entecavir	<20	27	24	1	1	3,17	3,15	3,16	3,02	2,82	ND	neg	neg	neg	neg
3		56	M	tenofovir	<20	38	54	ND	4	1,72	1,72	1,72	1,65	1,60	ND	neg	neg	neg	neg
4b		34	M	entecavir	<20	27	51	1	0	3,71	3,74	3,51	3,54	3,49	ND	neg	ND	neg	ND
5b		31	M	tenofovir	<20	28	28	1	0	4,07	3,97	3,99	4,13	3,98	ND	neg	neg	neg	ND
6		51	M	tenofovir	<20	22	35	ND	ND	3,08	2,99	3,04	3,05	3,05	2,80	neg	ND	neg	neg
7b		39	M	entecavir	<20	19	51	3	3	3,11	3,08	3,13	3,11	3,09	2,92	neg	neg	neg	neg
8		54	M	tenofovir	<20	23	29	2	2	3,41	3,32	3,34	3,16	3,08	ND	neg	ND	neg	neg
9		35	M	tenofovir	<20	35	38	2	4	3,39	3,28	3,36	3,19	3,12	ND	neg	neg	neg	ND
10b		48	F	lamivudine	<20	19	15	3	1	2,60	2,55	2,38	2,56	2,51	2,24	neg	neg	neg	neg
11		65	M	tenofovir	<20	30	25	1	4	0,61	0,61	0,18	0,18	-0,52	ND	neg	neg	neg	pos
12		37	M	entecavir	<20	43	35	2	1	4,32	4,30	4,21	4,14	4,42	ND	neg	neg	neg	ND
13b		62	F	lamivudine	<20	23	19	1	2	3,36	ND	3,40	3,22	3,35	ND	neg	neg	neg	neg
14b		35	M	tenofovir	<20	24	24	2	4	3,51	3,44	3,50	3,57	3,47	3,54	neg	neg	neg	ND
15b	NA + Peg-IFNα	41	M	entecavir	<20	28	39	3	2	3,66	3,55	3,53	3,00	3,53	3,37	neg	neg	neg	neg
16b		44	M	entecavir	<20	23	41	1	2	3,35	3,21	3,24	3,10	3,36	ND	neg	neg	neg	neg
17b		63	M	tenofovir	<20	31	42	1	1	2,93	2,97	2,83	2,59	2,65	ND	neg	neg	neg	ND
18		57	M	entecavir	<20	19	28	2	4	2,88	2,89	2,79	2,67	2,61	2,34	neg	neg	neg	neg
19b		49	M	entecavir	<20	32	20	ND	ND	3,90	3,78	2,70	1,28	3,26	2,90	neg	neg	neg	neg
20a,b		49	F	tenofovir	<20	17	13	1	2	2,38	2,24	2,36	2,20	1,61	ND	neg	neg	neg	ND
21b		67	M	tenofovir	<20	40	56	2	2	3,78	3,64	3,24	1,83	3,08	3,06	neg	neg	neg	neg
22		34	M	entecavir	<20	24	22	ND	ND	4,36	4,27	4,27	4,34	4,35	ND	neg	neg	neg	ND
23b		61	M	adefovir	<20	25	25	2	4	2,89	2,84	2,31	2,21	1,86	ND	neg	neg	ND	ND

a: patient stopped treatment after W12

b: patients HLA-A*02:01+

NA: nucleos(t)ide analog

ND: not determined.